Boston Scientific Climbs 40.5% in a Year: What's Driving the Stock?

Core Insights - Boston Scientific (BSX) has achieved a remarkable 40.5% increase in share price over the past year, significantly outperforming the industry and S&P 500 [1][9] - The company is currently ranked 2 (Buy) by Zacks, benefiting from the success of its WATCHMAN device and strong market share gains in the MedSurg segment [2][9] Company Overview - Boston Scientific, based in Marlborough, MA, specializes in developing, manufacturing, and marketing medical devices across various interventional medical specialties, focusing on less-invasive medical practices [3] - The company's R&D efforts are directed towards breakthrough technologies aimed at expanding existing markets and entering adjacent ones [3] Growth Catalysts - The growth in share price is attributed to the strong performance of the WATCHMAN left atrial appendage closure device, with sales increasing by 24% year-over-year in Q1 2025 [4] - The MedSurg segment is capturing market share, with notable growth in endoscopy, urology, and neuromodulation areas [5] - Electrophysiology growth accelerated in Q1 2025, with a 145% organic growth rate driven by the FARAPULSE PFA System, which surpassed $1 billion in global revenues [6] - Recent acquisitions, including Bolt Medical, Cortex, and Axonics, have expanded the product portfolio and contributed to organic revenue growth [7][9] Emerging Markets and Sales Growth - The company is actively expanding its presence in emerging markets, which saw a 9.8% operational growth year-over-year in Q1 2025, despite geopolitical challenges [11] - The Zacks Consensus Estimate projects a 16.4% revenue growth to $19.50 billion in 2025, followed by a 10.7% increase to $21.58 billion in 2026 [13]